medigraphic.com

2016, Número 4

<< Anterior Siguiente >>

Rev Hosp Jua Mex 2016; 83 (4)


Estrategias para inhibir a HMGB1 liberado durante la sepsis

Rivera-Pérez RJ, Sevilla-González ML, Flores-Estrada JJ

Idioma: Español
Referencias bibliográficas: 55
Paginas: 142-147
Archivo PDF: 164.65 Kb.


RESUMEN

La proteína HMGB1 (high mobility group box 1) fue descubierta como una proteína cromosómica no histónica participando en varios eventos relacionados con la actividad del ADN y en la transcripción génica. Más adelante se descubrió que HMGB1 es como mediador de fase tardía de la respuesta inflamatoria y se han identificado varios receptores que regulan su actividad extracelular en múltiples procesos celulares. La localización intracelular y extracelular de HMGB1 juega papeles significativamente diferentes en la inflamación, lesiones y cáncer. En la sepsis, HMGB1 es liberada tardíamente como un patrón molecular asociado a un daño celular (DAMP) y como un regulador de la autofagia durante la respuesta inmune. Numerosas estrategias para inhibir su liberación y actividad han sido estudiadas. Aquí revisamos brevemente algunas evidencias sobre su función y su posible uso como un blanco potencial terapéutico en enfermedades inflamatorias como la sepsis.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29(7): 1303-10.

  2. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 2007; 35(5): 1244-50.

  3. Vincent JL, Opal SM, Marshall JC, Tracey KJ. Sepsis definitions: time for change. Lancet 2013; 381(9868): 774-5.

  4. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330(6149): 662-4.

  5. Dinarello CA, Thompson RC. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 1991; 12(11): 404-10.

  6. Kim JH, Kim SJ, Lee IS, Lee MS, Uematsu S, Akira S, Oh KI. Bacterial endotoxin induces the release of high mobility group box 1 via the IFN-beta signaling pathway. J Immunol 2009; 182(4): 2458-66.

  7. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285(5425): 248-51.

  8. Malarkey CS, Churchill ME. The high mobility group box: the ultimate utility player of a cell. Trends Biochem Sci 2012; 37(12): 553-62.

  9. Sharman AC, Hay-Schmidt A, Holland PW. Cloning and analysis of an HMG gene from the lamprey Lampetra fluviatilis: gene duplication in vertebrate evolution. Gene 1997; 184(1): 99-105.

  10. Bustin M. Revised nomenclature for high mobility group (HMG) chromosomal proteins. Trends Biochem Sci 2001; 26(3): 152-3.

  11. Giavara S, Kosmidou E, Hande MP, Bianchi ME, Morgan A, d’Adda di Fagagna F, et al. Yeast Nhp6A/B and mammalian Hmgb1 facilitate the maintenance of genome stability. Curr Biol 2005; 15(1): 68-72.

  12. Wu D, Ding Y, Wang S, Zhang Q, Liu L. Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathology 2008; 216(2): 167-75.

  13. Kang R. Chen R, Zhang Q, Hou W, Wu S, Cao L, et al. HMGB1 in health and disease. Mol Aspects Med 2014; 40: 1-116.

  14. Goodwin GH, Sanders C, Johns EW. A new group of chromatinassociated proteins with a high content of acidic and basic amino acids. Eur J Biochem 1973; 38(1): 14-9.

  15. Wang H, Zhu S, Zhou R, Li W, Sama AE. Therapeutic potential of HMGB1-targeting agents in sepsis. Expert Rev Mol Med 2008; 10: e32.

  16. Tang D, Billiar TR, Lotze MT. A Janus tale of two active high mobility group box 1 (HMGB1) redox states. Mol Med 2012; 20; 18: 1360-2.

  17. Chen HG, Xie KL, Han HZ, Wang WN, Liu DQ, Wang GL, et al. Heme oxygenase-1 mediates the anti-inflammatory effect of molecular hydrogen in LPS-stimulated RAW 264.7 macrophages. Int J Surg 2013; 11(10): 1060-6.

  18. Ha YM, Kim MY, Park MK, Lee YS, Kim YM, Kim HJ, et al. Higenamine reduces HMGB1 during hypoxia-induced brain injury by induction of heme oxygenase-1 through PI3K/Akt/ Nrf-2 signal pathways. Apoptosis 2012; 17(5): 463-74.

  19. Kim HS, Park EJ, Park SW, Kim HJ, Chang KC. A tetrahydroisoquinoline alkaloid THI-28 reduces LPS-induced HMGB1 and diminishes organ injury in septic mice through p38 and PI3K/Nrf2/HO-1 signals. Int Immunopharmacol 2013; 17(3): 684-92.

  20. Wichterman KA, Baue AE, Chaudry IH. Sepsis and septic shock—a review of laboratory models and a proposal. J Surg Res 1980; 29(2): 189-201.

  21. Li W, Zhu S, Zhang Y, Sama AE, Wang P, Wang H. Use of animal model of sepsis to evaluate novel herbal therapies. J Vis Exp 2012; (62): pii: 3926.

  22. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285(5425): 248-51.

  23. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004; 101(1): 296-301.

  24. Wang H, Yang H, Czura CJ, Sama AE, Tracey KJ. HMGB1 as a Late Mediator of Lethal Systemic Inflammation. Am J Respir Crit Care Med 2001; 164(10, Pt. 1): 1768-73.

  25. Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. HMG- 1 as a mediator of acute lung inflammation. J Immunol 2000; 165(6): 2950-4.

  26. Suda K, Kitagawa Y, Ozawa S, Saikawa Y, Ueda M, Ebina M, et al. Anti-high-mobility group box chromosomal protein 1 antibodies improve survival of rats with sepsis. World J Surg 2006; 30(9): 1755-62.

  27. Li W, Li J, Sama AE, Wang H. Carbenoxolone blocks endotoxininduced protein kinase R (PKR) activation and high mobility group box 1 (HMGB1) release. Mol Med 2013; 19: 203-11.

  28. Lu B, Nakamura T, Inouye K, Li J, Tang Y, Lundback P, et al. Novel role of PKR in inflammasome activation and HMGB1 release. Nature 2012; 488(7413): 670-4.

  29. Hwang JS, Kang ES, Ham SA, Yoo T, Lee H, Paek KS, et al. Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone inhibits lipopolysaccharide-induced release of high mobility group box 1. Mediators Inflamm 2012; 2012: 352-7.

  30. Yang Z, Klionsky DJ. Mammalian autophagy: core molecular machinery and signaling regulation. Curr Opin Cell Biol 2010; 22(2): 124-31.

  31. Reggiori F, Komatsu M, Finley K, Simonsen A. Autophagy: more than a nonselective pathway. Int J Cell Biol 2012; 2012: 219625.

  32. Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, et al. Endogenous HMGB1 regulates autophagy. J Cell Biol 2010; 190(5): 881-92.

  33. Tang D, Kang R, Livesey KM, Kroemer G, Billiar TR, Van Houten B, et al. High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab 2011; 13(6): 701-11.

  34. Luo Y, Yoneda J, Ohmori H, Sasaki T, Shimbo K, Eto S, et al. Cancer usurps skeletal muscle as an energy repository. Cancer Res 2014; 74(1): 330-40.

  35. Kang R, Tang D, Livesey KM, Schapiro NE, Lotze MT, Zeh HJ 3rd. The Receptor for Advanced Glycation End-products (RAGE) protects pancreatic tumor cells against oxidative injury. Antioxid Redox Signal 2011; 15(8): 2175-84.

  36. Hagiwara S, Iwasaka H, Hasegawa A, Kudo K, Kusaka J, Oyama Y, et al. Infusion of a glucose solution reduces autophagy in the liver after LPS-induced systemic inflammation. Inflammation 2012; 35(1): 249-58.

  37. Yanai H, Matsuda A, An J, Koshiba R, Nishio J, Negishi H, et al. Conditional ablation of HMGB1 in mice reveals its protective function against endotoxemia and bacterial infection. Proc Natl Acad Sci USA 2013; 110(51): 20699-704.

  38. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med 2008; 36(1): 296-327.

  39. Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995; 23(7): 1294-303.

  40. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345(19): 1368-77.

  41. Hagiwara S, Iwasaka H, Hasegawa A, Asai N, Noguchi T. High-dose intravenous immunoglobulin G improves systemic inflammation in a rat model of CLP-induced sepsis. Intensive Care Med 2008; 34(10): 1812-9.

  42. Hagiwara S, Iwasaka H, Matsumoto S, Noguchi T. High dose antithrombin III inhibits HMGB1 and improves endotoxininduced acute lung injury in rats. Intensive Care Med 2008; 34(2): 361-7.

  43. Li W, Zhu S, Li J, Huang Y, Zhao R, Fan X, et al. A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation. PLoS ONE 2011; 6(2): e6945.

  44. Hagiwara S, Iwasaka H, Hasegawa A, Koga H, Noguchi T. Effects of hyperglycemia and insulin therapy on high mobility group box 1 in endotoxin-induced acute lung injury in a rat model. Crit Care Med 2008; 36(8): 2407-13.

  45. Chorny A, Delgado M. Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1. Am J Pathol 2008; 172(5): 1297-307.

  46. Chorny A, Anderson P, Gonzalez-Rey E, Delgado M. Ghrelin protects against experimental sepsis by inhibiting high-mobility group box 1 release and by killing bacteria. J Immunol 2008; 180(12): 8369-77.

  47. Chen G, Li J, Qiang X, Czura CJ, Ochani M, Ochuni K, et al. Suppression of HMGB1 release by stearoyl lysophosphatidylcholine: an additional mechanism for its therapeutic effects in experimental sepsis. J Lipid Res 2005; 46(4): 623-7.

  48. Hu YM, Pai MH, Yeh CL, Hou YC, Yeh SL. Glutamine administration ameliorates sepsis-induced kidney injury by downregulating the high-mobility group box protein-1-mediated pathway in mice. Am J Physiol Renal Physiol 2012; 302(1): F150-F158.

  49. Wang H, Li W, Li J, Rendon-Michell B, Ochani M, Ashok M, et al. The aqueous extract of a popular herbal nutrient supplement, Angelica sinensis, protects mice against lethal endotoxemia and sepsis. J Nutr 2006; 136(2): 360-5.

  50. Li W, Li J, Ashok M, Wu R, Chen D, Yang L, et al. A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1. J Immunol 2007; 178(6): 3856-64.

  51. Li W, Ashok M, Li J, Yang H, Sanam AE, Wang H. A Major Ingredient of Green Tea Rescues Mice from Lethal Sepsis Partly by Inhibiting HMGB1. PLoS ONE 2007; 2(11): e1153.

  52. Li W, Zhu S, Li J, Assa A, Jundoria A, Xu J, et al. EGCG stimulates autophagy and reduces cytoplasmic HMGB1 levels in endotoxin-stimulated macrophages. Biochem Pharmacol 2011; 81(9): 1152-63.

  53. Zhang Y, Li W, Zhu S, Jundoria A, Li J, Yang H, et al. Tanshinone IIA sodium sulfonate facilitates endocytic HMGB1 uptake. Biochem Pharmacol 2012; 84(11): 1492-500.

  54. Lu B, Wang H, Andersson U, Tracey KJ. Regulation of HMGB1 release by inflammasomes. Protein Cell 2013; 4(3): 163-7.

  55. Seo ES, Oh BK, Pak JH, Yim SH, Gurunathan S, Kim YP, et al. Acteoside improves survival in cecal ligation and punctureinduced septic mice via blocking of high mobility group box 1 release. Mol Cells 2013; 35(4): 348-54.




2020     |     www.medigraphic.com